Literature DB >> 22706215

Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa.

David A Lewis1, Tobias F Chirwa, Veerle M Y Msimang, Frans M Radebe, Mary L Kamb, Cynthia S Firnhaber.   

Abstract

BACKGROUND: To determine sexually transmitted infection (STI) prevalence, and patient characteristics associated with detection of urethritis/cervicitis pathogens, among HIV-infected individuals offered voluntary STI screening at a South African HIV treatment center.
METHODS: Individuals, asymptomatic for genital discharge, were screened for Neisseria gonorrhoeae (NG), Chlamydia trachomatis, Trichomonas vaginalis (TV), Mycoplasma genitalium (MG) infections (real-time polymerase chain reaction assay), for syphilis and herpes simplex type 2 (serologically), and for bacterial vaginosis and Candida (microscopy, women only). Patients' most recent CD4 and viral load results were recorded. Demographic, clinical, and behavioral data were collected by nurse-administered questionnaire.
RESULTS: Compared with men (n = 551), women (n = 558) were younger (mean age, 35.0 vs. 37.9 years; P < 0.001), reported more STIs in the past year (65.5% vs. 56.5%; P = 0.002), had more urethritis/cervicitis pathogens detected (21.3% vs.16.4%, P = 0.035), and were less aware of their partner's HIV status (53.1% vs. 62.3%; P = 0.007). The overall prevalence of individual urethritis/cervicitis pathogens was TV (7.6%), MG (6.1%), NG (5.4%), and C. trachomatis (2.1%). Multivariate analysis highlighted 4 significant factors associated with the detection of specific urethritis/cervicitis pathogens, namely female gender (TV, adjusted odds ratio [aOR] 2.53, 95% confidence interval [CI]: 1.47-4.37), having a regular sexual partner in the past 3 months (NG, aOR 2.26, 95% CI: 1.01-5.08), suboptimal condom use with regular partners (TV, aOR 2.07, 95% CI: 1.25-3.42), and a history of genital warts in the past year (NG, 2.25, 95% CI: 1.26-4.03).
CONCLUSIONS: Asymptomatic urethritis/cervicitis pathogens were highly prevalent in this population. Few urethritis/cervicitis pathogen-associated patient characteristics were identified, emphasizing the need for affordable STI diagnostics to screen HIV-infected patients.

Entities:  

Mesh:

Year:  2012        PMID: 22706215     DOI: 10.1097/OLQ.0b013e31824cbecc

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  16 in total

1.  Prevalence and Correlates of Genital Infections Among Newly Diagnosed Human Immunodeficiency Virus-Infected Adults Entering Human Immunodeficiency Virus Care in Windhoek, Namibia.

Authors:  Gaston Djomand; Madeleine Schlefer; Steve Gutreuter; Sarah Tobias; Roopal Patel; Nickolas DeLuca; Julia Hood; Souleymane Sawadogo; Cheng Chen; Alexinah Muadinohamba; David W Lowrance; Naomi Bock
Journal:  Sex Transm Dis       Date:  2016-11       Impact factor: 2.830

2.  Genital infections and syndromic diagnosis among HIV-infected women in HIV care programmes in Kenya.

Authors:  Gaston Djomand; Hongjiang Gao; Benson Singa; Sureyya Hornston; Eddas Bennett; James Odek; R Scott McClelland; Grace John-Stewart; Naomi Bock
Journal:  Int J STD AIDS       Date:  2015-01-22       Impact factor: 1.359

3.  Direct questioning is more effective than patient-initiated report for the detection of sexually transmitted infections in a primary care HIV clinic in Western Kenya.

Authors:  Victoria Gah Hay Woo; Craig R Cohen; Elizabeth A Bukusi; Megan J Huchko
Journal:  Sex Transm Dis       Date:  2013-02       Impact factor: 2.830

4.  Quality of Sexually Transmitted Infection Case Management Services in Gauteng Province, South Africa: An Evaluation of Health Providers' Knowledge, Attitudes, and Practices.

Authors:  David Cal Ham; Susan Hariri; Mary Kamb; Jennifer Mark; Ricky Ilunga; Sara Forhan; Mupatal Likibi; David A Lewis
Journal:  Sex Transm Dis       Date:  2016-01       Impact factor: 2.830

5.  High burden of STIs among HIV-infected adults prior to initiation of ART in South Africa: a retrospective cohort study.

Authors:  Mark N Lurie; Kipruto Kirwa; Johann Daniels; Marcel Berteler; Seth C Kalichman; Catherine Mathews
Journal:  Sex Transm Infect       Date:  2014-05-16       Impact factor: 3.519

Review 6.  Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations.

Authors:  Deborah L Couldwell; David A Lewis
Journal:  Infect Drug Resist       Date:  2015-05-26       Impact factor: 4.003

7.  Association between Mycoplasma genitalium infection and HIV acquisition among female sex workers in Uganda: evidence from a nested case-control study.

Authors:  Judith Vandepitte; Helen A Weiss; Justine Bukenya; Nassim Kyakuwa; Etienne Muller; Anne Buvé; Patrick Van der Stuyft; Richard J Hayes; Heiner Grosskurth
Journal:  Sex Transm Infect       Date:  2014-03-31       Impact factor: 3.519

8.  Prevalence and predictors of asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae in a Ugandan population most at risk of HIV transmission.

Authors:  Emily Mabonga; Yukari C Manabe; Ali Elbireer; Joshua K Mbazira; Maria S Nabaggala; Agnes Kiragga; Jennifer Kisakye; Charlotte A Gaydos; Chris Taylor; Rosalind Parkes-Ratanshi
Journal:  Int J STD AIDS       Date:  2021-02-20       Impact factor: 1.359

9.  A Comparative Analysis of Risky Sexual Behaviors, Self-Reported Sexually Transmitted Infections, Knowledge of Symptoms and Partner Notification Practices among Male and Female University Students in Pretoria, South Africa.

Authors:  Mathildah Mpata Mokgatle; Sphiwe Madiba; Lindiwe Cele
Journal:  Int J Environ Res Public Health       Date:  2021-05-25       Impact factor: 3.390

10.  High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options.

Authors:  Marcus J Pond; Achyuta V Nori; Adam A Witney; Rose C Lopeman; Philip D Butcher; Syed Tariq Sadiq
Journal:  Clin Infect Dis       Date:  2013-11-26       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.